1. Home
  2. MIRM vs ESNT Comparison

MIRM vs ESNT Comparison

Compare MIRM & ESNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mirum Pharmaceuticals Inc.

MIRM

Mirum Pharmaceuticals Inc.

N/A

Current Price

$86.88

Market Cap

5.4B

Sector

Health Care

ML Signal

N/A

Logo Essent Group Ltd.

ESNT

Essent Group Ltd.

N/A

Current Price

$57.52

Market Cap

5.9B

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
MIRM
ESNT
Founded
2018
2008
Country
United States
Bermuda
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Property-Casualty Insurers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
5.4B
5.9B
IPO Year
2019
2013

Fundamental Metrics

Financial Performance
Metric
MIRM
ESNT
Price
$86.88
$57.52
Analyst Decision
Strong Buy
Buy
Analyst Count
12
7
Target Price
$114.67
$67.86
AVG Volume (30 Days)
763.1K
643.1K
Earning Date
05-06-2026
05-08-2026
Dividend Yield
N/A
2.45%
EPS Growth
74.59
0.73
EPS
N/A
6.90
Revenue
$19,138,000.00
$1,260,935,000.00
Revenue This Year
$26.22
N/A
Revenue Next Year
$21.77
$3.18
P/E Ratio
N/A
$8.29
Revenue Growth
N/A
1.45
52 Week Low
$36.88
$51.61
52 Week High
$109.28
$67.09

Technical Indicators

Market Signals
Indicator
MIRM
ESNT
Relative Strength Index (RSI) 40.71 37.37
Support Level $85.76 $56.84
Resistance Level $96.65 $61.99
Average True Range (ATR) 3.90 1.01
MACD -0.38 -0.00
Stochastic Oscillator 16.52 23.74

Price Performance

Historical Comparison
MIRM
ESNT

About MIRM Mirum Pharmaceuticals Inc.

Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

About ESNT Essent Group Ltd.

Essent Group Ltd serves the housing finance industry by providing private mortgage insurance, reinsurance, risk management products, title insurance, and settlement services to mortgage lenders, borrowers, and investors to support homeownership. It provides credit protection to lenders and mortgage investors by covering a portion of the unpaid principal balance of a mortgage and certain related expenses in the event of a default. By providing capital to mitigate mortgage credit risk, the company allows lenders to make additional mortgage financing available to prospective homeowners.

Share on Social Networks: